Lv5
1540 积分 2021-03-16 加入
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
3天前
已完结
Foritinib, a type II ROS1 inhibitor for NSCLC
3天前
已完结
OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
3天前
已完结
[Clinical practice guideline for brain metastases of lung cancer in China (2021 version)]
24天前
已完结
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
1个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
1个月前
已完结
[Chinese expert consensus on the combination of immune checkpoint inhibitors and radiotherapy for lung cancer (2025 edition)]
1个月前
已完结
[Expert consensus on immunotherapy for small cell lung cancer (2025 edition)]
1个月前
已完结
[Perioperative immunotherapy for non-small cell lung cancer: consensus and controversy (2024 edition)]
1个月前
已完结
Abstract CT219: Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study
3个月前
已关闭
皖公网安备34019202002308
